Shirkadda AI Drug Exscientia waxay ururisay $60 Milyan oo Taxane C ah Maalgelinta 

Shirkadda horumarinta dawooyinka ee Ingiriiska ee Exscientia ayaa soo ururisay $60 milyan wareeggii maalgelinta ee taxanaha C. Waxa hogaaminaysay Danmark Novo Holdings, oo ah maalgeliyaha cusub, oo ay weheliyaan maalgashadayaasha jira Evotec, Bristol Myers Squibb, iyo GT Healthcare Capital.

Wareega maalgelinta ayaa ku soo beegmaya iyadoo ay jirto xiisaha sii kordhaya ee helitaanka daroogada AI ay wado, waxayna ka caawin doontaa shirkadda inay ballaariso si caalami ah, iyada oo si gaar ah diiradda loo saarayo joogitaanka Mareykanka. 

Prof. Andrew Hopkins waa maamulaha guud iyo aasaasaha Exscientia. 

"Maalgelintani waxay muujinaysaa ballanqaadka sii kordhaya ee suurtogalka ah ee AI si loo beddelo helitaanka daroogada iyo farxadda aan ka helnay shaqada cusub ee aan ka qabaneyno Exscientia," ayuu yiri Hopkins. "Waxaan hadda soo bandhignay dhowr jeer in barnaamijkeenu uu dardargelin karo waqtiga u dhexeeya bilowga fikradda iyo musharraxa cusub ee daroogada ee bukaannada u baahan daawaynta, si dhakhso leh loola socdo dhammaan geeddi-socodka R&D."

Robert Ghenchev waa lammaane sare iyo madaxa kobaca Novo, kaas oo ah gacanta kobaca sinnaanta ee Novo Holdings. 

"Iyadoo loo marayo rikoodhkeeda cajiibka ah ee taariikhda, Exscientia waxay muujisay qiimaha isku-darka khibradda cilmi-baarista qoto dheer ee awoodaha tikniyoolajiyada casriga ah si loo dardargeliyo helitaanka daroogada," ayuu yiri Ghenchev. Maalgelinta Novo Holdings waxay hoosta ka xariiqday xiisaha aan u qabno taageeridda shirkadaha tignoolajiyada ee suurtageliya cilmi-baarista sayniska nolosha iyo hal-abuurka, iyo sida ay nooga go'an tahay aaggan. Waxaan u aragnaa fursad muhiim ah shirkadu si ay u sii kobocdo ka qaybqaadashadeeda nidaamka deegaanka ee daahfurka daroogada waxaanan ku faraxsanahay inay la shaqeyso kooxda Exscientia xaqiijinta aragtidan."

Dr. Werner Lanthaler waa madaxa fulinta ee Evotec. 

"Evotec wuxuu ahaa maalgeliyaha ugu horreeya ee istaraatiijiyadeed iyo hawl-gal ee Exscientia, aad ayaan ugu faraxsanahay inay samaysay horumar la yaab leh tan iyo wakhtigaas iyo inaan qayb ka noqonno lacag ururintan muhiimka ah. Evotec iyo Exscientia, si wada jir ah, waxay rajeynayaan inay ogaadaan awood dheeraad ah oo isku-dhafan oo lagu heli karo dawooyinka cusub, "ayuu yiri Lanthaler.

Shirkaddu waxay ururisay $26 milyan, 18 bilood ka dib, oo ay ka heshay maalgashadayaasha ay ku jiraan Bristol Myers Squibb iyo Evotec.

Waa maxay Exscientia?

Exscientia waxay ku taal Oxford, shirkadduna waxay u isticmaashaa sirdoonka macmal ah helitaanka daroogada molecule yar. Horraantii sanadkan, shirkaddu waxay iskaashi la samaysay Sumitomo Dainippon Pharma (DSP) si ay u horumariyaan. daawadii ugu horaysay, sax ah-engineered loogu talagalay iyadoo la isticmaalayo AI. Daroogadu waxay u adeegtaa sidii daawaynta xanuunka waswaaska ah (OCD), waxayna gashay wajigii 1aad ee tijaabooyinka caafimaad ee aadanaha. Mashruuca oo dhami wuxuu socday wax ka yar 12 bilood, habkaas oo dhaqan ahaan qaadanaya 4.5 sano oo leh habab caadi ah. 

Tan iyo markaas, Exscientia waxa ay la samaysatay iskaashi mashruucyo badan leh Bristol Myers Squibb, Bayer, Rallybio, iyo GT Apeiron. 

Covid-19 

Shirkaddu waxay sidoo kale ka qayb qaadatay horumarinta daawaynta COVID-19. Adduunka oo dhan, shirkadaha dawooyinka iyo warshadaha biotech ayaa iska kaashaday si ay diiradda u saaraan horumarinta tallaalka iyo daaweynta fayraska.

Dabayaaqadii bishii Maarso, Exscientia waxay ku dhawaaqday in shirkaddu ay iskaashi la samaynayso Isha Dheeman Light, xarun saynis oo fadhigeedu yahay Oxfordshire, iyo sidoo kale soo-saare daroogada Calibr, si ay ula timaado daawaynta ka hortagga fayraska ee COVID-19.